Free Pre-Market Technical Pulse on AVEO Pharma and Three More Biotech Stocks

Stock Research Monitor: AYTU, BLCM, and BCRX

LONDON, UK / ACCESSWIRE / June 25, 2018 / If you want a free Stock Review on AVEO sign up now at www.wallstequities.com/registration. In today's pre-market research reports, WallStEquities.com monitors AVEO Pharmaceuticals Inc. (NASDAQ: AVEO), Aytu BioScience Inc. (NASDAQ: AYTU), Bellicum Pharmaceuticals Inc. (NASDAQ: BLCM), and BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX). These stocks are part of the Biotech industry, which focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. As per Investopedia, biotechnology companies are almost always unprofitable (some suggest that the distinction between "biotech" and "pharmaceutical" company lies in profitability), and many have no real revenue at all. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

AVEO Pharmaceuticals

Last Friday, shares in Cambridge, Massachusetts-based AVEO Pharmaceuticals Inc. ended the session 4.35% higher at $2.40. The stock recorded a trading volume of 2.89 million shares, which was above its three months average volume of 1.64 million shares. The Company's shares have advanced 2.13% in the last month and 229.76% over the past year. The stock is trading above its 50-day moving average by 1.66%. Furthermore, shares of AVEO Pharma, which develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need, have a Relative Strength Index (RSI) of 56.47. Get the full research report on AVEO for free by clicking below at:

www.wallstequities.com/registration/?symbol=AVEO

Aytu BioScience

Englewood, Colorado-based Aytu BioScience Inc.'s stock finished 6.02% lower at $0.31 with a total trading volume of 489,279 shares. The stock is trading below their 50-day moving average by 23.44%. Shares of the Company, which focuses on developing and commercializing novel products in the field of urology in the US, has an RSI of 36.83.

On June 13th, 2018, Aytu BioScience announced that it has exclusively licensed Zolpimist™ (zolpidem tartrate oral spray) in the US and Canada. Zolpimist is an FDA-approved, proprietary, oral spray formulation of zolpidem tartrate and is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Download our actionable research report on AYTU at:

www.wallstequities.com/registration/?symbol=AYTU

Bellicum Pharmaceuticals

Shares in Houston, Texas headquartered Bellicum Pharmaceuticals Inc. closed the day 4.06% higher at $7.95. The stock recorded a trading volume of 982,997 shares. The Company's shares have gained 5.86% over the previous three months. The stock is trading below its 50-day moving average by 0.48%. Moreover, shares of Bellicum Pharma, which focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the US and internationally, have an RSI of 44.70.

On May 29th, 2018, Bellicum Pharma announced the appointment of Shane M. Ward as General Counsel and Corporate Secretary. Mr. Ward, who will report to CEO Rick Fair, will lead the legal, compliance, and corporate governance functions for the Company. Register for your free report coverage on BLCM at:

www.wallstequities.com/registration/?symbol=BLCM

BioCryst Pharmaceuticals

Durham, North Carolina headquartered BioCryst Pharmaceuticals Inc.'s shares recorded a trading volume of 1.02 million shares last Friday, which was above their three months average volume of 782,860 shares. The stock closed 3.12% lower at $5.59. The Company's shares have advanced 7.29% in the previous three months. The stock is trading 8.24% above its 200-day moving average. Additionally, shares of BioCryst Pharma, which designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases, have an RSI of 44.87.

On June 05th, 2018, BioCryst Pharma issued an open letter to stockholders. An excerpt of the letter follows: "BioCryst's Special Meeting of Stockholders is scheduled for July 10th, 2018. We urge you to vote today ‘FOR' the merger transaction with Idera Pharmaceuticals, Inc. using the enclosed proxy card. The BioCryst's Board of Directors believes this transaction represents a significant opportunity to enhance the value of your investment in BioCryst and unanimously recommends that stockholders vote ‘FOR' the transaction, which will create a new company to be called Valenscion Incorporated."

On June 22nd, 2018, research firm Seaport Global Securities initiated a 'Neutral' rating on the Company's stock. Get the free research report on BCRX at:

www.wallstequities.com/registration/?symbol=BCRX

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities